QuidelOrtho Corporation (QDEL) Stock Analysis
Healthcare · Medical Devices · NasdaqGS
QuidelOrtho Corporation (QDEL) posted $2.73B in revenue for fiscal 2025 (down 1.9% year over year), with a net loss of $1.13B, and has compounded revenue about 10.4%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on QuidelOrtho Corporation
QuidelOrtho Corporation has grown revenue from $1.66B to $2.73B over the last 6 fiscal years, compounding about 10.4% a year. The most recent year was down 1.9%, so growth has cooled from its longer-run pace.
Net margin sits at -41.5%, up 31.3 points year over year. It carries about $2.88B of total debt.
The one thing worth a second look in the filings is receivables growing faster than sales.
Synthesised from QuidelOrtho Corporation's SEC filings — descriptive, not advice. Ask the analyst your own question →
QuidelOrtho Corporation revenue & earnings — last 6 fiscal years
| Metric | 2021 | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.66B | $1.70B | $3.27B | $3.00B | $2.78B | $2.73B |
| Gross profit | — | — | — | — | — | — |
| Net income | $810.30M | $704.20M | $548.70M | $-10.10M | $-2.03B | $-1.13B |
| Net margin | 48.8% | 41.5% | 16.8% | -0.3% | -72.8% | -41.5% |
Source: QuidelOrtho Corporation SEC filings (10-K).
QuidelOrtho Corporation: 4 potential red flags in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Receivables growing faster than salesAccounts receivable rose 47.7% while revenue rose -1.9% in the latest year — a gap that can signal looser credit terms or pulled-forward sales. Worth checking days-sales-outstanding.
- Share count rising (dilution)Shares outstanding grew 62.8% over 4 years (41.7M → 67.9M) — existing holders' stakes are being diluted.
- Heavy debt loadTotal debt of $3054.3M is 29.0× last year's operating cash flow — it would take years of cash flow to clear.
- Currently unprofitableThe latest fiscal year was a net loss (net margin -41.5%).
Explore 6 years of QuidelOrtho Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track QDEL in your portfolio →
QuidelOrtho Corporation financial history by metric
Compare QuidelOrtho Corporation with peers
About QuidelOrtho Corporation
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.
QuidelOrtho Corporation — frequently asked questions
What is QuidelOrtho Corporation's revenue?
QuidelOrtho Corporation (QDEL) reported revenue of $2.73B for fiscal year 2025, down 1.9% from the prior year, according to its SEC filings.
Is QuidelOrtho Corporation profitable?
No — QDEL reported a net loss of $-1.13B in fiscal 2025.
What is QDEL's P/E ratio?
QuidelOrtho Corporation trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is QuidelOrtho Corporation growing?
QDEL's revenue grew at roughly 10.4% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does QuidelOrtho Corporation have?
As of fiscal year 2025, QDEL carried roughly $2.88B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is QuidelOrtho Corporation's market cap?
QuidelOrtho Corporation (QDEL) has a market capitalization of about $926.37M, based on the latest data in our nightly-refreshed cache.
When does QuidelOrtho Corporation's fiscal year end?
QDEL's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from QuidelOrtho Corporation's official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.